AZD 0233
Alternative Names: AZD-0233Latest Information Update: 23 May 2024
At a glance
- Originator AstraZeneca
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Dilated cardiomyopathy
Most Recent Events
- 01 Apr 2024 Phase-I clinical trials in Dilated cardiomyopathy (In volunteers) in USA (PO) (NCT06381466)